1. Home
  2. RENX vs ADTX Comparison

RENX vs ADTX Comparison

Compare RENX & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RenX Enterprises Corp. Common Stock

RENX

RenX Enterprises Corp. Common Stock

N/A

Current Price

$0.17

Market Cap

2.0M

Sector

N/A

ML Signal

N/A

Logo Aditxt Inc.

ADTX

Aditxt Inc.

HOLD

Current Price

$0.75

Market Cap

2.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RENX
ADTX
Founded
2021
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
2.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RENX
ADTX
Price
$0.17
$0.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.5M
2.6M
Earning Date
02-22-2026
11-18-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,970,752.00
$5,945.00
Revenue This Year
N/A
$15,768.94
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2770.15
N/A
52 Week Low
$0.16
$0.76
52 Week High
$2.74
$5,867.50

Technical Indicators

Market Signals
Indicator
RENX
ADTX
Relative Strength Index (RSI) N/A 33.75
Support Level N/A $0.81
Resistance Level N/A $0.97
Average True Range (ATR) 0.00 0.10
MACD 0.00 0.03
Stochastic Oscillator 0.00 3.55

Price Performance

Historical Comparison
RENX
ADTX

About RENX RenX Enterprises Corp. Common Stock

RenX Enterprises Corp is a real estate development and environmental solutions company. It is focused on the direct acquisition and indirect investment in properties across the United States that are intended for development into green single-family or multifamily housing projects. The company also focuses on the monetization of its real estate assets. It processes source-separated green waste and is expanding into the production of sustainable, high-margin potting media and soil substrates through advanced milling technology.

About ADTX Aditxt Inc.

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.

Share on Social Networks: